心脈醫療(688016.SH)：預計上半年淨利潤同比減少10.52%-24.78%
格隆匯7月14日丨心脈醫療(688016.SH)公佈，經公司財務部門初步測算，預計2025年上半年度實現營業收入70,845.72萬元到78,717.47萬元，與上年同期（法定披露數據）相比，將減少7,871.75萬元到0.00萬元，同比減少10.00%到0.00%。預計2025年上半年度實現歸屬於母公司所有者的淨利潤爲30,354.00萬元到36,109.00萬元，與上年同期（法定披露數據）相比，將減少9,998.36萬元到4,243.36萬元，同比減少24.78%到10.52%。
報告期內，公司創新性產品Castor分支型主動脈覆膜支架及輸送系統、Minos腹主動脈覆膜支架及輸送系統、ReewarmPTX藥物球囊擴張導管持續發力，新產品Talos?直管型胸主動脈覆膜支架系統及Fontus?分支型術中支架系統入院家數及終端植入量均增長較快，但考慮到2024年下半年市場環境變化，公司產品價格及推廣策略的調整因素，2025年上半年銷售額增速及利潤仍受到一定影響。2025年上半年，公司研發項目有較多突破。創新研發的全新一代Cratos?分支型主動脈覆膜支架系統上市並實現臨牀植入；Tipspear?經頸靜脈肝內穿刺套件獲批上市。Hector?胸主動脈多分支覆膜支架系統正式獲批進入國家藥品監督管理局（NMPA）創新醫療器械特別審查程序，該產品用於微創傷介入治療累及主動脈弓部三分支的胸主動脈瘤，這是公司第9款進入國家創新醫療器械審批“綠色通道”的產品，同時在海外完成了多例臨牀植入。報告期內，公司榮獲“2024年度浦東新區先進製造業突出貢獻獎”，公司核心產品Castor?分支型主動脈覆膜支架的專利技術正式獲得第二十五屆中國專利金獎。此外，Vflower?靜脈支架系統等多個產品入選2025年度上海市生物醫藥創新產品攻關項目及浦東新區生物醫藥產業高質量發展專項支持。截至目前，公司產品已在國內超過2700家醫院進入臨牀應用，覆蓋全國31個省、自治區、直轄市及港澳地區，國際業務拓展至40餘個國家和地區。其中，報告期內，Minos?腹主動脈覆膜支架及輸送系統和Hercules?球囊擴張導管先後成功獲得歐盟CEMDR（MedicalDeviceRegulation(EU)2017/745）認證。未來，公司將繼續加大對外投資，深化全球化佈局，爲全球患者提供更優質的醫療器械產品和服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
